Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences ...
Fast track designation accelerates development of [68Ga]Ga-DPI-4452 for ccRCC detection, enhancing FDA engagement and review processes. ITM-94, a gallium-68-radiolabeled PET agent, forms a theranostic ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC. According to the authors, “ADVC001 is a novel PSMA ...
In an interview at the 2025 LUGPA Annual Meeting, Stacy Loeb, MD, shared key takeaways from her session, “Current state of prostate cancer screening.” Loeb is a urologists at NYU Langone Health in New ...
A panel of experts discusses the evolution of BPH treatment, as well as how their practices have been affected by COVID-19.
Hear from 5 experts as they recap some of the top data from this year's ESMO Congress. Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates ...
The KEYNOTE-905 trial showed significant survival benefits with enfortumab vedotin and pembrolizumab in muscle-invasive bladder cancer, suggesting a new standard for cisplatin-ineligible patients. The ...
An expert discusses how proactive referral, multidisciplinary coordination, and early identification can optimize outcomes for patients with muscle-invasive bladder cancer, especially those with ...
The government shutdown affects urology practices through halted CMS policy work and temporary Medicare payment disruptions. Expiration of Medicare telehealth flexibilities impacts rural and ...
The Avvio ELS has received FDA breakthrough device designation, enhancing its development and review process for treating ureteral stones. The system uses microbubble enhanced acoustic cavitation ...
The gemcitabine intravesical system offers localized chemotherapy delivery, providing a promising option for patients who have failed previous treatments. Successful implementation of new therapies ...
177Lu-PSMA-617 addition to ADT and ARPI significantly improved rPFS in PSMA-positive mHSPC patients, with consistent benefits across subgroups. The PSMAddition trial showed a trend toward improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback